AA
RPRX icon

AlphaCentric Advisors’s Royalty Pharma RPRX Stock Holding History

AlphaCentric Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-67,500
Closed -$1.91M – 272
2024
Q3 		$1.91M Buy
67,500
+7,500
+13% +$208K 1.42% 22
2024
Q2 		$1.58M Hold
60,000
– – 1.17% 24
2024
Q1 		$1.82M Buy
60,000
+20,000
+50% +$590K 1.1% 28
2023
Q4 		$1.12M Buy
+40,000
New +$1.1M 0.75% 49

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AlphaCentric Advisors's RPRX Position: Q4 2024 in Review

AlphaCentric Advisors sold out of Royalty Pharma (RPRX) in Q4 2024, closing a stake of 67,500 shares — an estimated $1.91M sold.

AlphaCentric Advisors first reported a position in RPRX in Q4 2023 and held it in 4 quarters. The position peaked at $1.91M in Q3 2024. 417 funds tracked by Wall St. Rank hold RPRX as of Q4 2024.

  • AlphaCentric Advisors reported no remaining Royalty Pharma position as of Q4 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 67,500 Royalty Pharma shares in Q4 2024, an estimated $1.91M.
  • AlphaCentric Advisors first reported a position in Royalty Pharma in Q4 2023 and held it in 4 quarters.
  • AlphaCentric Advisors's Royalty Pharma position peaked at $1.91M in Q3 2024.
  • 417 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2024.

Based on AlphaCentric Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.